Ashvattha Therapeutics Presents Preclinical Data on anti-VEGF Nanomedicine D-4517.2 at the 2023 ARVO Annual Meeting
26 avr. 2023 13h30 HE
|
Ashvattha Therapeutics
Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions to a level comparable to D-4517.2 delivered subcutaneously and Aflibercept...
Ashvattha Therapeutics Presented Promising Preclinical Data on Novel Macrophage Switching Nanomedicine D-4559 at AACR Annual Meeting
18 avr. 2023 09h00 HE
|
Ashvattha Therapeutics
Data demonstrated D-4559 switches tumor associated macrophages from an M2 to M1 pro-inflammatory phenotype leading to reduction in tumor growth in a mouse model of hepatocellular carcinomaThe data...
Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings
03 avr. 2023 08h30 HE
|
Ashvattha Therapeutics
Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a potent macrophage switching nanomedicine, on reducing tumor growth in a mouse model of hepatocellular...
Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent
06 févr. 2023 08h30 HE
|
Ashvattha Therapeutics
– The study will evaluate the safety, tolerability and ability of [18F]OP-801 to cross the blood brain barrier and selectively target neuroinflammation in individuals with ALS and healthy volunteers –...
Ashvattha Therapeutics to Present at Upcoming Investor Conferences
02 févr. 2023 08h30 HE
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a...
Ashvattha Therapeutics to Present at Biotech Showcase 2023
03 janv. 2023 08h30 HE
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a...
Ashvattha Therapeutics Announces the Appointment of Steve Maricich, M.D., Ph.D. as Chief Medical Officer
20 oct. 2022 08h30 HE
|
Ashvattha Therapeutics
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that...
Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress
29 sept. 2022 15h14 HE
|
Ashvattha Therapeutics
– Data demonstrated [18F]OP-801 is a promising tracer for imaging activated macrophages/microglia with high sensitivity in the lumbar spine of a murine model of multiple sclerosis (MS) – – Treatment...
Ashvattha Therapeutics Announces Presentations of Preclinical Data on Hydroxyl Dendrimer-Based PET Tracer [18F]OP-801 at the 2022 World Molecular Imaging Congress (WMIC)
15 sept. 2022 08h00 HE
|
Ashvattha Therapeutics
– Scientific collaborators at Stanford University will present data on an imaging and treatment regimen demonstrating the microglial targeting of [18F]OP-801 in a mouse model of multiple sclerosis and...
Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 2 Study of D-4517.2 for the Treatment of Wet AMD and DME
07 sept. 2022 08h00 HE
|
Ashvattha Therapeutics
– First patient was enrolled as part of a two-stage Phase 2 study evaluating Ashvattha’s subcutaneous (SC) anti-VEGF wet AMD and DME candidate, D-4517.2 – – The first stage of the study will evaluate...